Logo image of CRI.PA

CHARGEURS SA (CRI.PA) Stock Fundamental Analysis

EPA:CRI - Euronext Paris - Matif - FR0000130692 - Common Stock - Currency: EUR

11.9  +0.06 (+0.51%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CRI. CRI was compared to 15 industry peers in the Industrial Conglomerates industry. CRI may be in some trouble as it scores bad on both profitability and health. CRI is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CRI has reported negative net income.
CRI had a positive operating cash flow in the past year.
CRI had positive earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CRI reported negative operating cash flow in multiple years.
CRI.PA Yearly Net Income VS EBIT VS OCF VS FCFCRI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

1.2 Ratios

The Return On Assets of CRI (-0.55%) is worse than 93.33% of its industry peers.
Looking at the Return On Equity, with a value of -1.81%, CRI is doing worse than 93.33% of the companies in the same industry.
CRI has a worse Return On Invested Capital (3.61%) than 66.67% of its industry peers.
CRI had an Average Return On Invested Capital over the past 3 years of 4.83%. This is below the industry average of 7.16%.
Industry RankSector Rank
ROA -0.55%
ROE -1.81%
ROIC 3.61%
ROA(3y)1.98%
ROA(5y)2.57%
ROE(3y)6.62%
ROE(5y)8.73%
ROIC(3y)4.83%
ROIC(5y)5.7%
CRI.PA Yearly ROA, ROE, ROICCRI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 5 10 15

1.3 Margins

In the last couple of years the Profit Margin of CRI has declined.
CRI has a Operating Margin of 4.76%. This is in the lower half of the industry: CRI underperforms 73.33% of its industry peers.
CRI's Operating Margin has declined in the last couple of years.
CRI has a worse Gross Margin (26.99%) than 93.33% of its industry peers.
CRI's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 4.76%
PM (TTM) N/A
GM 26.99%
OM growth 3Y-18.6%
OM growth 5Y-11.57%
PM growth 3Y-64.16%
PM growth 5Y-45.18%
GM growth 3Y-0.45%
GM growth 5Y-0.47%
CRI.PA Yearly Profit, Operating, Gross MarginsCRI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 5 10 15 20 25

More info and screens

1

2. Health

2.1 Basic Checks

CRI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
CRI has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for CRI has been increased compared to 5 years ago.
Compared to 1 year ago, CRI has a worse debt to assets ratio.
CRI.PA Yearly Shares OutstandingCRI.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
CRI.PA Yearly Total Debt VS Total AssetsCRI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 1.47, we must say that CRI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CRI (1.47) is worse than 73.33% of its industry peers.
CRI has a debt to FCF ratio of 50.42. This is a negative value and a sign of low solvency as CRI would need 50.42 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 50.42, CRI is doing worse than 66.67% of the companies in the same industry.
A Debt/Equity ratio of 1.06 is on the high side and indicates that CRI has dependencies on debt financing.
The Debt to Equity ratio of CRI (1.06) is worse than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 50.42
Altman-Z 1.47
ROIC/WACC0.53
WACC6.86%
CRI.PA Yearly LT Debt VS Equity VS FCFCRI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

CRI has a Current Ratio of 1.29. This is a normal value and indicates that CRI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.29, CRI is doing worse than 86.67% of the companies in the same industry.
A Quick Ratio of 0.83 indicates that CRI may have some problems paying its short term obligations.
CRI has a worse Quick ratio (0.83) than 86.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 0.83
CRI.PA Yearly Current Assets VS Current LiabilitesCRI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

CRI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -137.41%.
The earnings per share for CRI have been decreasing by -44.13% on average. This is quite bad
Looking at the last year, CRI shows a decrease in Revenue. The Revenue has decreased by -0.75% in the last year.
The Revenue has been growing slightly by 2.64% on average over the past years.
EPS 1Y (TTM)-137.41%
EPS 3Y-67.43%
EPS 5Y-44.13%
EPS Q2Q%-254.53%
Revenue 1Y (TTM)-0.75%
Revenue growth 3Y-7.38%
Revenue growth 5Y2.64%
Sales Q2Q%8.62%

3.2 Future

The Earnings Per Share is expected to grow by 32.83% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 6.24% on average over the next years.
EPS Next Y44.78%
EPS Next 2Y88.98%
EPS Next 3Y64.08%
EPS Next 5Y32.83%
Revenue Next Year7.65%
Revenue Next 2Y9.24%
Revenue Next 3Y8.48%
Revenue Next 5Y6.24%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRI.PA Yearly Revenue VS EstimatesCRI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
CRI.PA Yearly EPS VS EstimatesCRI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

CRI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 10.92 indicates a reasonable valuation of CRI.
Based on the Price/Forward Earnings ratio, CRI is valued a bit cheaper than the industry average as 73.33% of the companies are valued more expensively.
CRI is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 10.92
CRI.PA Price Earnings VS Forward Price EarningsCRI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

CRI's Enterprise Value to EBITDA ratio is in line with the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CRI is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 37.93
EV/EBITDA 10.04
CRI.PA Per share dataCRI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20 25

4.3 Compensation for Growth

CRI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CRI's earnings are expected to grow with 64.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y88.98%
EPS Next 3Y64.08%

More info and screens

1

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 1.10%, CRI has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 3.65, CRI's dividend is way lower than its industry peers. On top of this 86.67% of the companies listed in the same industry pay a better dividend than CRI!
Compared to an average S&P500 Dividend Yield of 2.33, CRI's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 1.1%

5.2 History

The dividend of CRI decreases each year by -5.16%.
Dividend Growth(5Y)-5.16%
Div Incr Years0
Div Non Decr Years0
CRI.PA Yearly Dividends per shareCRI.PA Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2025 0.5 1 1.5

5.3 Sustainability

DP0%
EPS Next 2Y88.98%
EPS Next 3Y64.08%
CRI.PA Yearly Income VS Free CF VS DividendCRI.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M

More info and screens

CHARGEURS SA

EPA:CRI (3/7/2025, 7:00:00 PM)

11.9

+0.06 (+0.51%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryIndustrial Conglomerates
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)09-03 2025-09-03
Inst Owners10.24%
Inst Owner ChangeN/A
Ins Owners64.27%
Ins Owner ChangeN/A
Market Cap295.83M
Analysts76
Price Target14.24 (19.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.1%
Yearly Dividend0.36
Dividend Growth(5Y)-5.16%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.01%
PT rev (3m)5.28%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.58%
EPS NY rev (3m)-8.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)0.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.92
P/S 0.44
P/FCF 37.93
P/OCF 13.51
P/B 1.01
P/tB N/A
EV/EBITDA 10.04
EPS(TTM)-0.21
EYN/A
EPS(NY)1.09
Fwd EY9.15%
FCF(TTM)0.31
FCFY2.64%
OCF(TTM)0.88
OCFY7.4%
SpS27.14
BVpS11.75
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.55%
ROE -1.81%
ROCE 4.94%
ROIC 3.61%
ROICexc 4.35%
ROICexgc 9.61%
OM 4.76%
PM (TTM) N/A
GM 26.99%
FCFM 1.16%
ROA(3y)1.98%
ROA(5y)2.57%
ROE(3y)6.62%
ROE(5y)8.73%
ROIC(3y)4.83%
ROIC(5y)5.7%
ROICexc(3y)6.41%
ROICexc(5y)7.76%
ROICexgc(3y)14.55%
ROICexgc(5y)16.89%
ROCE(3y)6.63%
ROCE(5y)7.87%
ROICexcg growth 3Y-36.63%
ROICexcg growth 5Y-17.87%
ROICexc growth 3Y-33.41%
ROICexc growth 5Y-18.68%
OM growth 3Y-18.6%
OM growth 5Y-11.57%
PM growth 3Y-64.16%
PM growth 5Y-45.18%
GM growth 3Y-0.45%
GM growth 5Y-0.47%
F-Score5
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 50.42
Debt/EBITDA 5.39
Cap/Depr 55.95%
Cap/Sales 2.09%
Interest Coverage 250
Cash Conversion 38.22%
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 0.83
Altman-Z 1.47
F-Score5
WACC6.86%
ROIC/WACC0.53
Cap/Depr(3y)52.41%
Cap/Depr(5y)65.81%
Cap/Sales(3y)2.06%
Cap/Sales(5y)2.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-137.41%
EPS 3Y-67.43%
EPS 5Y-44.13%
EPS Q2Q%-254.53%
EPS Next Y44.78%
EPS Next 2Y88.98%
EPS Next 3Y64.08%
EPS Next 5Y32.83%
Revenue 1Y (TTM)-0.75%
Revenue growth 3Y-7.38%
Revenue growth 5Y2.64%
Sales Q2Q%8.62%
Revenue Next Year7.65%
Revenue Next 2Y9.24%
Revenue Next 3Y8.48%
Revenue Next 5Y6.24%
EBIT growth 1Y-6.41%
EBIT growth 3Y-24.61%
EBIT growth 5Y-9.23%
EBIT Next Year169.06%
EBIT Next 3Y57.99%
EBIT Next 5YN/A
FCF growth 1Y262.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y204.17%
OCF growth 3YN/A
OCF growth 5YN/A